This study is testing a drug called AMDX-2011P in people with Cerebral Amyloid Angiopathy (CAA), a condition where proteins build up in the brain's blood vessels. The main goal is to see if AMDX-2011P is safe and well-tolerated when given as a single injection. Researchers will also look at how the drug moves through the body and if it has any biological effects. You might be able to join if you are 18 or older and have a diagnosis of CAA, confirmed by genetic testing or specific brain imaging (MRI) criteria. The study aims to enroll 25 participants, but its current recruitment status is unclear.

Study design

This is an open-label study, meaning you and the study team will know you are receiving AMDX-2011P. It involves a single treatment and aims to enroll 25 participants.

What's involved

You would be admitted to the study site for an eye exam and retinal imaging before receiving a single intravenous (IV) injection of AMDX-2011P. Afterward, safety checks, more retinal imaging, and blood draws will be performed.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be assessed for 8 days after receiving the AMDX-2011P injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.